Abstract C39: Phase I clinical trial of CX‐4945: A first‐in‐class orally administered small molecule inhibitor of protein kinase CK2
Keyword(s):
Phase I
◽
2013 ◽
2010 ◽
Vol 28
(15_suppl)
◽
pp. e13522-e13522
◽
Keyword(s):
2010 ◽
Vol 9
(5)
◽
pp. 1136-1146
◽
Keyword(s):
Keyword(s):
2004 ◽
Vol 64
(13)
◽
pp. 4394-4399
◽
Keyword(s):